The global antiviral drugs market is poised for steady expansion, projected to reach a valuation of USD 89.68 billion by 2033, up from USD 61.42 billion in 2023, growing at a Compound Annual Growth ...

MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of ...

NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (t ...

Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...

Center at UCSF is pioneering the development of potent drug candidates aimed at preventing future coronavirus pandemics. Researchers at UC San Francisco and the Gladstone Institutes have developed new ...

NanoViricides, Inc. (NYSE American: NNVC) provided a strategic update on its antiviral pipeline, highlighting NV-387 as a potential breakthrough trea ...

PPIs like omeprazole (Prilosec) and esomeprazole (Nexium) are widely used to treat heartburn and acid reflux. Long-term use ...

“This trial brings us closer to realizing ProLectin-M's potential as a first-line antiviral," said Dr. Leslie Ajayi, Bioxytran's Chief Medical Officer. "The consistency of our results, including 100% ...

The antiviral drug tecovirimat has been approved in Europe to treat mpox, on the basis of animal studies. But a clinical trial involving people infected with a concerning version of the monkeypox ...

BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clinical stage biotechnology company developing novel antiviral therapies, today announced the ...

The antiviral baloxavir significantly reduced household transmission of influenza compared with placebo. The drug showed consistent effects across age groups, virus types, and countries ...